Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922009 | 0.86 | KDM4E (0.52) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL1923630 | 0.80 | KDM4E (0.48) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL1921582 | 0.73 | KDM4E (0.53) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL1923001 | 0.70 | KDM4E (0.70) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL3838328 | 0.69 | KDM4E (0.69) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL7706563 | 0.68 | KDM4E (0.61) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL1420044 | 0.68 | KDM4E (0.61) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL7687272 | 0.68 | KDM4E (0.61) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL1922261 | 0.68 | KDM4E (0.61) | KDM4EKMT2AALOX15HSD17B10MEN1 | |
| SCHEMBL7712450 | 0.68 | KDM4E (0.61) | KDM4EKMT2AALOX15HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2327408-A1 | Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy | ICOS Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2036560-A1 | (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy | ICOS Corporation (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| EP-0828479-B1 | METHOD OF PRODUCING A SOLID DISPERSION OF A POORLY WATER SOLUBLE DRUG | ICOS CORP (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6143746-A | Combination of tadalafil and another drug for cGMP-specific PDE inhibition; erectile dysfunction, cardiovascular disorders | ICOS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6025494-A | CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
| US-5985326-A | MIXING WITH SOLVENT; COPRECIPITATION; 2,3,6,7,12,12A-HEXAHYDRO-2-METHYL-6-(3,4-METHYLENEDIOXYPHENYL) -PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONE | ICOS CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | KDM4E 1370/4885KMT2A 1547/4885ALOX15 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.